A Randomized, Double-Blinded, Placebo-Controlled Study of the Effect of XmAb®5871 on Systemic Lupus Erythematosus Disease Activity

Trial Profile

A Randomized, Double-Blinded, Placebo-Controlled Study of the Effect of XmAb®5871 on Systemic Lupus Erythematosus Disease Activity

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Mar 2018

At a glance

  • Drugs XmAb 5871 (Primary)
  • Indications Immunological disorders; Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Sponsors Xencor
  • Most Recent Events

    • 27 Feb 2018 According to a Xencor media release, company expect to announce initial data from this study in 4Q of 2018.
    • 05 Jan 2018 According to a Xencor media release, enrollment was completed in the Phase 2 trial in SLE in December 2017.
    • 05 Jan 2018 Status changed from recruiting to active no longer recruiting, according to a Xencor media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top